The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Application of different routes of octreotide administration in the treatment of malignant bowel obstruction
Pages: 505-508
Year: Issue:  5
Journal: Oncology Progress

Abstract: Objective To investigate the effectiveness of 0.2 mg octreotide injected subcutaneously every 8 hours and 25 μg/h octreotide given by continuous intravenous pumping in the treatment of malignant bowel obstruction. Method Totally 102 cases of patients with malignant bowel obstruction were enrolled and divided into subcutaneous injection group (n=52) and continuous intravenous pumping group (n=50) by simple randomization method. The improvement of clinical symptoms, drainage of gastrointestinal tract decompression, electrolyte level, Karnofsky score (KPS score) and adverse reactions were recorded for these two groups on day 0, day 3, day 5 and day 7 during the period of therapy. Re-sult When compared with the conditions before treatment, the vomiting episodes and drainage of gastrointestinal tract de-compression decreased, abdominal pain was alleviated, KPS score was improved, the serum potassium, sodium and chlo-ride levels increased after treatment, and all the differences reached statistical significance (P<0.05). However, there was no statistically significant difference of curative effect between two administration routes(P>0.05). Conclusion Both oc-treotide subcutaneous injection and continuous intravenous pumping routes can significantly improve the symptoms and reduce the drainage of gastrointestinal tract in patients with malignant bowel obstruction. These two administration routes have equivalent curative effects without any serious adverse reactions. Of the two administration routes, subcutaneous in-jection has less impact on patients'daily life, and is more acceptable to patients.
Related Articles
No related articles found